Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

238 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-23

Study Completion Date

2022-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

NCT04362930

Neurologic Manifestations Psychiatric Disorders COVID-19

COMPLETED

Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients

NCT04546737

Covid19 Neurological Manifestations Brain Damage

UNKNOWN NA

Neural and Cognitive Consequences of COVID-19 Survival

NCT06208943

COVID Long-Haul COVID-19 COVID-19 Pandemic +4 more

RECRUITING

COVID19 Neurological Manifestation

NCT04496128

SARS-CoV 2 Neurologic Manifestations

COMPLETED

COVID-19 and the Brain

NCT04726176

Covid19 Brain Neurocognition +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Neurologic Manifestations Psychiatric Manifestations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Covid-19 infection

Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period

Group Type EXPERIMENTAL

blood sample

Intervention Type OTHER

blood sample for serum (serology, biomarkers) and DNA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample for serum (serology, biomarkers) and DNA

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age over 18 yo
2. Patient having presented or presenting a Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
3. And patient with:

1. a neurological or psychiatric manifestation de novo during or after the Covid-19 infection and/or
2. either a chronic neurological or psychiatric pathology

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No